title: Is brimonidine ophthalmic a safe therapy for infants?
abstract: Brimonidine is a topical alpha-2 agonist commonly used in the treatment of glaucoma. Brimonidine toxicity resembles that of clonidine overdose and is probably due to both imidazoline and alpha-2 adrenergic receptor effects. We report a case of a 6-week-old infant with congenital glaucoma who developed bradycardia and hypotension following the administration of brimonidine 0.15% ophthalmic solution. There are occasional reports of brimonidine toxicity in the paediatric population but its overall safety profile in children<2 years of age remains uncertain. Brimonidine is not dosed by weight and therefore paediatric patients may be at increased risk for systemic toxicity. It is recommended that the use of this medication be carefully considered in children<2 years of age. Physicians should be aware of its side effect profile because of its general use in the paediatric population.
authors.affiliation: Department of Emergency Medicine & Pediatrics, Children's Hospital of Michigan Regional Poison Control Center, Wayne State University School of Medicine, Detroit, MI, USA. gpat-md@sbglobal.net
authors.forename: G P
authors.initials: GP
authors.lastname: Daubert
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001919:Bradycardia / Q000139:chemically induced; D000068438:Brimonidine Tartrate; D005901:Glaucoma / Q000151:congenital / Q000188:drug therapy; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007223:Infant; D008297:Male; D009883:Ophthalmic Solutions; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000316:Adrenergic alpha-Agonists; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate